Heidelberg Epignostix, a Heidelberg, Germany-based precision most cancers diagnostics startup, raised €4.3M in Seed funding.
The spherical was led by CARMA FUND I Capital GmbH & Co KG, with participation from Excessive-Tech Gründerfonds, LBBW Enterprise Capital GmbH and Begin-up BW Seed Fonds.
The corporate intends to make use of the funds to broaden its improvement efforts for its flagship indication for mind tumor classification.
Heidelberg Epignostix is a healthcare firm aiming to remodel most cancers diagnostics although information science. It has developed novel AI-based bioinformatics algorithms with utility in most cancers classification for improved accuracy in most cancers prognosis, prognosis and remedy administration. The lead product, the Heidelberg Mind Tumor Classifier, is at present obtainable as a research-use-only useful resource.
Combining epigenetics with synthetic intelligence-powered bioinformatics, the software program algorithms allow exact most cancers classification of subtypes which are in any other case tough or unimaginable to differentiate. The know-how relies on DNA methylation which is a sample of chemical tags on tumor DNA functioning as genomic fingerprints. The algorithm has been utilized to greater than 150,000 affected person samples to this point.
FinSMEs
08/07/2024
